EA201691871A1 - Растворы силденафила и способы их получения и применения - Google Patents

Растворы силденафила и способы их получения и применения

Info

Publication number
EA201691871A1
EA201691871A1 EA201691871A EA201691871A EA201691871A1 EA 201691871 A1 EA201691871 A1 EA 201691871A1 EA 201691871 A EA201691871 A EA 201691871A EA 201691871 A EA201691871 A EA 201691871A EA 201691871 A1 EA201691871 A1 EA 201691871A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
sildenafile
solutions
production
application
Prior art date
Application number
EA201691871A
Other languages
English (en)
Other versions
EA032819B1 (ru
Inventor
Моше Рогосницки
Моррис Абухи
Original Assignee
Вигорус Солюшнс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691871(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вигорус Солюшнс Лтд. filed Critical Вигорус Солюшнс Лтд.
Publication of EA201691871A1 publication Critical patent/EA201691871A1/ru
Publication of EA032819B1 publication Critical patent/EA032819B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00Details of, or arrangements associated with, antennas
    • H01Q1/27Adaptation for use in or on movable bodies
    • H01Q1/28Adaptation for use in or on aircraft, missiles, satellites, or balloons
    • H01Q1/288Satellite antennas
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00Details of, or arrangements associated with, antennas
    • H01Q1/36Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q5/00Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
    • H01Q5/50Feeding or matching arrangements for broad-band or multi-band operation
    • H01Q5/55Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Astronomy & Astrophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Remote Sensing (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к композициям, содержащим растворенный цитрат силденафила, и к способам получения таких композиций, в которых цитрат силденафила растворен в воде, смешанной с одним или несколькими спиртами, и, необязательно, может быть использован кетон для улучшения растворимости. Изобретение также относится к способам применения таких композиций, содержащих растворенный цитрат силденафила, с применением доз, которые значительно ниже существующих терапевтических доз цитрата силденафила.
EA201691871A 2014-03-19 2015-03-19 Растворы силденафила и способы их получения и применения EA032819B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955299P 2014-03-19 2014-03-19
PCT/IB2015/052014 WO2015140748A2 (en) 2014-03-19 2015-03-19 Sildenafil solutions and methods of making and using same

Publications (2)

Publication Number Publication Date
EA201691871A1 true EA201691871A1 (ru) 2017-03-31
EA032819B1 EA032819B1 (ru) 2019-07-31

Family

ID=54145440

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691871A EA032819B1 (ru) 2014-03-19 2015-03-19 Растворы силденафила и способы их получения и применения

Country Status (24)

Country Link
US (2) US9968609B2 (ru)
EP (2) EP3372083A1 (ru)
JP (1) JP6744821B2 (ru)
KR (1) KR20160137584A (ru)
CN (1) CN106132204B (ru)
AU (2) AU2015233006B2 (ru)
CA (1) CA2942628C (ru)
CL (1) CL2016002318A1 (ru)
CY (1) CY1120187T1 (ru)
DK (1) DK3119201T3 (ru)
EA (1) EA032819B1 (ru)
ES (1) ES2668915T3 (ru)
HR (1) HRP20180773T1 (ru)
HU (1) HUE038431T2 (ru)
IL (1) IL247840B (ru)
LT (1) LT3119201T (ru)
MX (1) MX371276B (ru)
NO (1) NO2723977T3 (ru)
PL (1) PL3119201T3 (ru)
PT (1) PT3119201T (ru)
RS (1) RS57206B1 (ru)
SG (2) SG11201607507VA (ru)
SI (1) SI3119201T1 (ru)
WO (1) WO2015140748A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2723977T3 (ru) 2014-03-19 2018-03-10
JP6902372B2 (ja) * 2017-02-28 2021-07-14 ヱスビー食品株式会社 苦味抑制用組成物
AU2018397436A1 (en) * 2017-12-26 2020-08-13 Ftf Pharma Private Limited Liquid oral formulations for PDE V inhibitors
EP3956024A4 (en) * 2019-04-18 2023-01-11 Ellamed IP & Services Pte. Ltd. SILDENAFIL CITRATE LIQUID COMPOSITIONS
AU2020382492A1 (en) * 2019-11-12 2022-05-26 American Regent, Inc. Type V phosphodiesterase inhibitor compositions, methods of making them and methods of using them

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017675A1 (en) * 1993-02-05 1994-08-18 Kao Corporation Taste modifying method and bitter taste reducing method
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
CA2406930C (en) 2000-02-04 2011-02-15 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2002005820A1 (en) 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US20070065394A1 (en) 2003-11-17 2007-03-22 Pinney Virginia R Compositions effective in altering the perception of malodor
ATE387203T1 (de) 2004-01-05 2008-03-15 Teva Pharma Prozesse zur herstellung von sildenafil-base und zitratsalz
CN1925860A (zh) * 2004-01-05 2007-03-07 特瓦制药工业有限公司 制备西地那非碱及其柠檬酸盐的方法
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
ES2434944T5 (es) 2005-03-14 2022-10-20 Wyeth Llc Composiciones de tigeciclina y procedimientos de preparación
US7556487B2 (en) 2006-03-29 2009-07-07 Intergum Gida Sinayi ve Ticaret A.S. Apparatus for making center-filled chewing gum pieces
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
DE502008002360D1 (de) 2007-06-19 2011-03-03 Symrise Ag Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck
EP2072044A1 (en) * 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
WO2009125415A1 (en) 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
FR2939321B1 (fr) 2008-12-05 2011-08-26 Philippe Perovitch Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
DE102010049708A1 (de) * 2010-10-28 2012-05-03 Hexal Ag Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe
JP6047174B2 (ja) * 2011-12-05 2016-12-21 スダ リミテッド シルデナフィルの経口スプレー製剤及びその投与方法
GB2497933B (en) 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2013170655A1 (en) * 2012-05-16 2013-11-21 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
NO2723977T3 (ru) 2014-03-19 2018-03-10

Also Published As

Publication number Publication date
AU2018250378A1 (en) 2018-11-08
CN106132204B (zh) 2019-08-20
PT3119201T (pt) 2018-06-15
RS57206B1 (sr) 2018-07-31
SG11201607507VA (en) 2016-10-28
CN106132204A (zh) 2016-11-16
KR20160137584A (ko) 2016-11-30
EP3119201A4 (en) 2017-03-15
HUE038431T2 (hu) 2018-10-29
EA032819B1 (ru) 2019-07-31
CY1120187T1 (el) 2018-12-12
IL247840B (en) 2019-03-31
LT3119201T (lt) 2018-05-10
US20170049776A1 (en) 2017-02-23
MX2016012154A (es) 2016-12-15
CL2016002318A1 (es) 2017-03-24
CA2942628A1 (en) 2015-09-24
US20180233823A1 (en) 2018-08-16
ES2668915T3 (es) 2018-05-23
PL3119201T3 (pl) 2018-08-31
EP3119201A2 (en) 2017-01-25
MX371276B (es) 2020-01-23
NO2723977T3 (ru) 2018-03-10
CA2942628C (en) 2022-06-07
SG10201808038TA (en) 2018-10-30
US9968609B2 (en) 2018-05-15
JP2017508764A (ja) 2017-03-30
DK3119201T3 (en) 2018-05-28
WO2015140748A2 (en) 2015-09-24
AU2018250378B2 (en) 2020-05-14
SI3119201T1 (en) 2018-07-31
AU2015233006B2 (en) 2018-07-19
EP3119201B1 (en) 2018-03-14
HRP20180773T1 (hr) 2018-06-15
WO2015140748A3 (en) 2015-12-17
JP6744821B2 (ja) 2020-08-19
EP3372083A1 (en) 2018-09-12
US10211534B2 (en) 2019-02-19
AU2015233006A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
TN2017000452A1 (en) Compositions of obeticholic acid and methods of use
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
SA517381769B1 (ar) توليد حمض بيروكسي فورميك من خلال فورمات كحول بولي هيدريك
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MD20170070A2 (ru) Производные хиназолина, используемые при лечении ВИЧ
EA201692050A1 (ru) Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита
EA201692269A1 (ru) Новые композиции, их использование и способы получения
MX2020005446A (es) Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
MX2021010060A (es) Produccion de virus en huevos aviares.
EA201691871A1 (ru) Растворы силденафила и способы их получения и применения
CL2016002073A1 (es) Proceso para producir una solución inyectable de noradrenalina de baja concentración estable
CL2015002897A1 (es) Inhibidores de bace1
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
ES2601137T3 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201791845A1 (ru) Твердые формы менахинолов
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
PL405540A1 (pl) Sposób otrzymywania ksantohumolu
PH12016502311A1 (en) Omega-3 analogues
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
IN2014DE00883A (ru)
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.